🇺🇸

Amgen

Public

MariTide and next-gen peptide obesity programs

Amgen is a biotech mega-cap expanding into peptide obesity therapeutics via MariTide (maridebart cafraglutide), a GLP-1 receptor agonist + GIP receptor antagonist peptide-antibody conjugate with a monthly or less-frequent dosing profile. Amgen's peptide obesity pipeline represents its most significant growth bet of the decade.

Founded1980

HQThousand Oaks, CA

CEORobert A. Bradway

TickerNASDAQ:AMGN

Total FundingN/A (Public)

Pipeline

Drug / Program	Indication	Phase	Technology
MariTide (maridebart cafraglutide)	Obesity	Phase 3	GLP-1 RA + GIP RAnt peptibody
AMG 786	Obesity	Phase 1	Oral peptide

Key People

Robert A. BradwayChairman & CEO

Jay BradnerChief Scientific Officer